興科蓉醫藥(06833.HK)：透過訂立股權轉讓協議及借款協議以及擬定VIE合約安排收購德美公司以運營醫療美容醫院
格隆匯3月23日丨興科蓉醫藥(06833.HK)發佈公吿，2022年3月22日，四川興科蓉生物科技(公司全資附屬公司，作為股權轉讓協議A的買方及借款協議的貸款人)與中國股權擁有人(即執行董事黃祥彬先生之子黃智健先生，作為股權轉讓協議B的買方及借款交易的借款人)就收購事項各自訂立相關股權轉讓協議及借款協議(連同根據該等股權轉讓協議完成後將予訂立的一系列VIE合約安排)，總代價最高為人民幣9500萬元。
根據四川興科蓉生物科技(即買方)、擔保人、賣方(即廣漢火精靈電子商務有限責任公司)、目標公司(即德陽億思達生物科技有限公司)及德美公司訂立的股權轉讓協議A，賣方同意出售而買方同意向賣方收購目標公司的全部股權，代價最高為人民幣6650萬元。於該公吿日期，目標公司擁有及控制德美公司的70%股權。
根據中國股權擁有人(即買方)、蔣彪先生、張敏先生、廣漢浩正(作為賣方)、仁尚仁及德美公司訂立的股權轉讓協議B，廣漢浩正同意出售而中國股權擁有人同意收購仁尚仁的全部股權，代價最高為人民幣2850萬元。於該公吿日期，仁尚仁擁有及控制德美公司(即OPCO)的30%股權。根據四川興科蓉生物科技與中國股權擁有人訂立的借款協議，四川興科蓉生物科技同意借出而中國股權擁有人同意借入合共人民幣2850萬元，是項借款僅用於收購仁尚仁(其擁有及控制德美公司的30%股權)的全部股權。由於中國的外商投資限制及許可要求，四川興科蓉生物科技將與仁尚仁及OPCO及／或中國股權擁有人訂立一系列VIE合約安排，以防止股權及價值流向OPCO的少數股東並取得OPCO的最大經濟利益。
訂立VIE合約安排後，仁尚仁的全部財務業績及OPCO30%的財務業績將於本集團的綜合財務報表綜合入賬，仁尚仁將成為公司的間接全資附屬公司。根據股權轉讓協議完成及訂立擬進行的VIE合約安排後，德美公司將成為公司的全資附屬公司，德美公司的財務業績、資產及負債將於公司的綜合財務報表綜合入賬。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
